PRILACTONE NEXT 50 MG CHEWABLE TABLETS FOR DOGS

Maa: Irlanti

Kieli: englanti

Lähde: HPRA (Health Products Regulatory Authority)

Aktiivinen ainesosa:

SPIRONOLACTONE

Saatavilla:

Ceva Santé Animale

ATC-koodi:

QC03DA01

INN (Kansainvälinen yleisnimi):

SPIRONOLACTONE

Annos:

50 mg/tablet

Lääkemuoto:

Tablets Chewable

Prescription tyyppi:

POM

Terapeuttinen ryhmä:

Canine

Terapeuttinen alue:

Spironolactone

Käyttöaiheet:

Neurological Preparations

Valtuutuksen tilan:

Authorised

Valtuutus päivämäärä:

2016-04-22

Valmisteyhteenveto

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Prilactone Next 50 mg chewable tablets for dogs
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
One tablet contains
ACTIVE SUBSTANCE:
Spironolactone............................................................
50 mg
EXCIPIENT(S):
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Chewable tablet.
Clover-shaped scored beige tablet. The tablet can be divided into four
equal parts.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For use in combination with standard therapy (including diuretic
support, where necessary) for the treatment of
congestive heart failure caused by degenerative mitral valve disease
in dogs.
4.3 CONTRAINDICATIONS
Do not use in animals used for or intended for use in breeding.
Do not use the product in dogs suffering from hypoadrenocorticism,
hyperkalaemia or hyponatraemia.
Do not administer spironolactone in conjunction with NSAIDs to dogs
with renal insufficiency.
Do not use in the case of hypersensitivity to spironolactone or any of
the excipients.
See section 4.7.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_2_
_9_
_/_
_0_
_3_
_/_
_2_
_0_
_1_
_7_
_C_
_R_
_N_
_ _
_7_
_0_
_2_
_6_
_4_
_0_
_2_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Kidney function and plasma
potassium levels
sho